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Success rates of re-excision after positive margins for invasive
lobular carcinoma of the breast
Merisa L. Piper 1, Jasmine Wong2, Kelly Fahrner-Scott2, Cheryl Ewing2, Michael Alvarado2, Laura J. Esserman2 and Rita A. Mukhtar2
Rates of positive margins after surgical resection of invasive lobular carcinoma (ILC) are high (ranging from 18 to 60%), yet the
efficacy of re-excision lumpReceptor subtypeectomy for clearing positive margins is unknown. Concerns about the diffuse nature of
ILC may drive increased rates of completion mastectomy to treat positive margins, thus lowering breast conservation rates. We
therefore determined the success rate of re-excision lumpectomy in women with ILC and positive margins after surgical resection.
We identified 314 cases of stage I-III ILC treated with breast conserving surgery (BCS) at the University of California, San Francisco.
Surgical procedures, pathology reports, and outcomes were analyzed using univariate and multivariate statistics and Cox-
proportional hazards models. We evaluated outcomes before and after the year 2014, when new margin management consensus
guidelines were published. Positive initial margins occurred in 118 (37.6%) cases. Of these, 62 (52.5%) underwent re-excision
lumpectomy, which cleared the margin in 74.2%. On multivariate analysis, node negativity was significantly associated with
successful re-excision (odds ratio [OR] 3.99, 95% CI 1.15–13.81, p= 0.029). After 2014, we saw fewer initial positive margins (42.7%
versus 25.5%, p= 0.009), second surgeries (54.6% versus 20.2%, p < 0.001), and completion mastectomies (27.7% versus 4.5%, p <
0.001). In this large cohort of women with ILC, re-excision lumpectomy was highly successful at clearing positive margins.
Additionally, positive margins and completion mastectomy rates significantly decreased over time. These findings highlight
improvements in management of ILC, and suggest that completion mastectomy may not be required for those with positive
margins after initial BCS.
npj Breast Cancer            (2019) 5:29 ; https://doi.org/10.1038/s41523-019-0125-7
INTRODUCTION
Obtaining clear margins after surgical resection of breast cancer is
a well-documented challenge in the management of this disease,
and having unresected positive margins is associated with worse
outcomes.1–3 For invasive lobular carcinoma (ILC), the second
most common subtype of breast cancer, the issue of positive
margins is a particularly prevalent problem. ILC lacks the adhesion
protein E-cadherin, resulting in a diffuse pattern of tumor growth
in so-called “single file” lines of tumors cells. Additionally, imaging
tests often underestimate tumor size in ILC. The combination of a
diffuse growth pattern and high false negative rates on imaging
results in higher rates of positive margins compared to invasive
ductal carcinoma (IDC).4,5 Indeed, up to 60% of women with ILC
who undergo breast conservation surgery (BCS) will have positive
margins.2,6–12
For the large number of women who have positive margins
after partial mastectomy for ILC, they and their physicians must
decide whether to pursue re-excision in a continued attempt to
conserve the breast, versus completion mastectomy. Concerns
that re-excision lumpectomy will fail to clear the margin can result
in increased mastectomies, and in several series, women with ILC
who have positive or close margins are significantly more likely to
undergo completion mastectomy than women with IDC.2,12–15
While many investigators have reported on high positive margin
rates in ILC, to our knowledge there are scarce data reporting the
success rates of re-excision lumpectomy at clearing the initially
positive margin. Understanding the likelihood of success is critical
for patients to make informed decisions about whether to
continue to pursue breast conservation after an initial positive
margin, versus undergoing completion mastectomy.
Our primary goal, therefore, was to determine the success rate
of re-excision lumpectomy for positive margins after partial
mastectomy for ILC. Our secondary goals were to identify factors
associated with successful re-excision lumpectomy, to determine
the impact of persistently positive margins on disease free survival
(DFS), and lastly, to evaluate changes in the incidence and
management of positive margins before and after margin
consensus guidelines of 2014.
RESULTS
Patient characteristics
Average age at diagnosis was 61.8 years (range 30–97), 93.2% of
cases were estrogen receptor (ER) positive/human epidermal
growth factor receptor 2 (HER2) negative, and 62.0% of cases were
grade 2. The majority of patients had stage 1–2 disease, and
average follow up time was 6.1 years, ranging from 0.5 months to
26 years (Table 1).
Success rate of re-excisions for positive margins
In our cohort of 314 ILC cases treated with BCS, positive margins
occurred in 118 (37.6%). Of these, 102 cases had additional
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surgery, of which 62 were re-excision lumpectomies and the
remainder completion mastectomies. Among the 62 re-excision
lumpectomies for positive margins, 46 (74.2%) were successful,
meaning they resulted in negative margins, while 16 cases
resulted in positive margins again. Of these 16 cases with positive
margins after first attempt at re-excision, 8 (50%) underwent
completion mastectomy, 5 (31.3%) had a second re-excision
lumpectomy, and 3 (18.8%) had no further surgery (Fig. 1).
Among the 62 cases who had re-excision lumpectomies for
positive margins, we compared the successful re-excisions (n= 46)
to the unsuccessful re-excisions (n= 16) to identify factors
associated with higher likelihood of success. Between these
groups, there was no difference in rates of pleomorphic ILC,
lymphovascular invasion, tumor subtype by ER/PR/HER2 status,
grade, presence of lobular carcinoma in situ, or tumor multifocality
(Table 2). Mean tumor size was larger in those with unsuccessful
re-excision (3.1 cm versus 2.4 cm), but this difference did not reach
statistical significance. However, those with successful re-excision
had significantly less nodal involvement than those with
unsuccessful re-excision (mean of 1.3 positive nodes versus 4.6
positive nodes, p= 0.0298). Additionally, older women were
significantly more likely to have a successful re-excision lumpect-
omy (mean age 61.4 versus 55.1 years in successful versus
unsuccessful cases, p= 0.0445). In a logistic regression model
adjusting for age and nodal status, node negativity remained the
only significant predictor of successful re-excision (OR 3.99, 95% CI
1.15–13.81, p= 0.029).
Re-excisions for negative margins
There were patients who underwent a second surgery despite
having negative margins (defined as no ink on tumor) after initial
BCS. Among the 196 patients with negative margins, 37 (18.9%)
underwent re-excision (either re-excision lumpectomy or comple-
tion mastectomy, Fig. 1). Of the 175 negative margin cases with
margin width available, the average margin width was signifi-
cantly smaller among those who underwent second surgery
compared to those who did not undergo a second surgery
(1.27 mm versus 2.37 mm, respectively, p= 0.0118).
Unresected positive margins
Among the entire cohort of 314 ILC cases, 175 (55.7%) had a single
surgery, 117 (37.3%) had two surgeries, and 22 (7%) had
3 surgeries. BCS was successful in 246 (78.3%), with the remaining
cases undergoing completion mastectomy. Ultimately, 288
(91.7%) had negative margins, while 26 (8.3%) had unresected
positive margins (4 of which occurred despite completion
mastectomy). Of the 26 unresected positive margins, 16 (61.5%)
were either anterior or posterior, 8 (30.7%) were radial margins
(either superior, medial, lateral, or inferior), and 2 were of
unknown location. All unresected positive radial margins occurred
in BCS cases with no completion mastectomy performed. On
univariate Cox proportional hazards analysis, having a final
positive margin was significantly associated with shorter DFS
(HR 3.4, 95% CI 1.3–8.9, p= 0.014). However, when adjusting for
age, stage, tumor subtype, tumor grade, local therapy, and
adjuvant chemotherapy use, final margin status was no longer
significantly associated with DFS (HR 3.4, 95% CI 0.8–13.9, p=
0.087), while tumor grade (HR 10.3, 95% CI 1.13–94.3, p= 0.039)
and subtype (HR 6.1, 95% CI 1.3–27.5, p= 0.02) remained
significant predictors of DFS (Table 3).
Era of treatment
Finally, we evaluated the impact of era of treatment before and
after 1 January 2014. While the definition of adequate margins in
clinical practice has varied over time, in 2014 Society of Surgical
Oncology (SSO)/American Society for Radiation Oncology (ASTRO)
consensus guidelines defined adequate margins as no ink on
tumor.16 In our cohort, positive margin rates, re-excision rates for
both positive and negative margins, and completion mastectomy
rates were significantly higher prior to 2014 (Table 4). We
specifically evaluated rates of re-excision for margin width
≤1mm, and found significantly higher re-excision rates prior to
2014 (50% versus 15.6%, p= 0.001). Of the 37 re-excisions
performed for negative margins (no ink on tumor), 35 (94.6%)
were performed prior to 2014.
DISCUSSION
In this analysis of outcomes for a large cohort of women with ILC
undergoing BCS, we found that when re-excision lumpectomy was
attempted to clear positive margins, it was successful 74.2% of the
time (46 out of 62 re-excision lumpectomies). Those with smaller
tumors, older age, and lower burden of nodal involvement had
the highest rates of successful re-excision lumpectomy. However,
the only significant predictor of successful re-excision lumpect-
omy was node negative status (which the majority [76.1%] of
these patients had). Currently, women with ILC have high rates of
Table 1. Patient and tumor characteristics
Characteristic N (%)
Age, years [median (range)] 61.3 (30–97)
Post-menopausala 181 (73.6%)
Tumor gradeb
1 103 (33.4%)
2 191 (62.0%)
3 14 (4.6%)
Receptor subtypec
ER+/PR+/HER2− 216 (78.3%)
ER+/PR−/HER2− 41 (14.9%)
HER2+ 14 (5.1%)
Triple negative 5 (1.8%)
Lymphovascular invasion 18 (5.7%)
Presence of lobular carcinoma in situd 232 (75.1%)
Tumor multifocality 97 (31.3%)
Pleomorphic ILC 31 (9.9%)
Nodal stage
N0 239 (76.1%)
N1 47 (15.0%)
N2 11 (3.5%)
N3 17 (5.4%)
Tumor stage
T1 194 (61.8%)
T2 96 (30.6%)
T3 24 (7.6%)
Overall stage
1 244 (77.7%)
2 50 (15.9%)
3 20 (6.4%)
Follow-up time, years [median (range)] 4.5 (0.5–26)
Data are expressed as n (%) unless otherwise specified
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal
growth factor receptor 2
aData available in n= 246; bdata available in n= 308; cdata available in n=
276; ddata available in n= 309
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completion mastectomies in the setting of positive margins
following attempted BCS. An institutional series of over 10,000
breast cancer patients undergoing BCS found that 62.7% of the
1215 ILC patients had a completion mastectomy.17 Our data
suggest that for women with ILC who have positive margins after
BCS, attempting a re-excision lumpectomy is reasonable and likely
to be successful. These high rates of completion mastectomy may
not be necessary in all women with ILC who have positive
margins.
Achieving a clear margin, however, is still an important goal in
the surgical management of ILC. On univariate analysis, those
patients with persistently positive margins had significantly worse
DFS. The impact of positive margins was mitigated when adjusting
Fig. 1 Flow chart of outcomes of patients with ILC who initially underwent BCS
Table 2. Factors associated with successful re-excision lumpectomy
Successful
re-excision
lumpectomy
(n= 46)
Unsuccessful
re-excision
(n= 16)
p-value
Age in years (mean,
median, [range])
61.4, 60.7
(43.7–80.4)
55.1, 52.6
(44.7–78.8)
0.0445
Post menopausal 25 (71.4%) 6 (54.6%) NS
Tumor grade (n= 61)
1 16 (35.6%) 7 (43.8%) NS
2 27 (60%) 9 (56.3%)
3 2 (4.4%) 0 (0%)
Receptor subtype
ER+/PR+/HER2− 33 (78.6%) 11 (73.3%) NS
ER+/PR−/HER2− 8 (19.1%) 3 (20%)
HER2+ 1 (2.4%) 1 (6.7%)
Lymphovascular
invasion
7 (15.2%) 1 (6.3%) NS
Presence of LCIS 37 (82.2%) 14 (87.5%) NS
Tumor multifocality 21 (46.7%) 9 (60%) NS
Pleomorphic 4 (8.7%) 1 (6.3%) NS
Lymph node positive 12 (26.1%) 10 (62.5%) 0.009
N stage 0.029
0 34 (73.9%) 6 (37.5%)
1 8 (17.4%) 5 (31.3%)
2 1 (2.2%) 2 (12.5%)
3 3 (6.5%) 3 (18.8%)
Mean tumor size
(cm, SD)
2.4, 1.6 3.1, 2.3 NS
T stage NS
1 27 (58.7%) 7 (43.8%)
2 15 (32.6%) 4 (25%)
3 4 (8.7%) 5 (31.3%)
Era of treatment NS
Before 2014 36 (73.5%) 13 (26.5%)
2014–2018 10 (76.9%) 3 (23%)
NS not significant, SD standard deviation
Table 3. Cox proportional hazards model for DFS
HR p-value 95% CI
Age at diagnosis 0.97 0.247 0.92–1.02
Stage
1 Reference
2 0.37 0.361 0.045–3.08
3 0.62 0.664 0.072–5.35
Receptor subtype
ER+/PR+/HER2– Reference
ER+/PR-/HER2– 6.1 0.020 1.33–27.47
HER2+ 0 N/A N/A
Triple negative 0 N/A N/A
Grade
Low/intermediate Reference
High 10.3 0.039 1.13–94.28
Final positive margins 3.41 0.087 0.84–13.89
Local therapy
Lumpectomy with radiation Reference
Lumpectomy alone 0.78 0.769 0.15–4.0
Mastectomy 1.8 0.371 0.49–6.62
Mastectomy with radiation 0 N/A N/A
Adjuvant chemotherapy 0.8 0.725 0.22–2.83
DFS disease-free survival, HR hazard ratio, CI confidence interval, N/A not
applicable
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for other factors on multivariate analysis, but the trend towards
decreased DFS remained. Whether or not margin width impacts
DFS was beyond the scope of this analysis, but the significant
change in margin management over time seen in our cohort will
require ongoing study to evaluate long term outcomes. Similar to
other reports, we found that after publication of SSO/ASTRO
consensus guidelines in 2014, the rate of re-excision for close
margins was markedly reduced.18 This appeared to translate into
far fewer completion mastectomies (27.7% completion mastect-
omy rate prior to 2014, compared to 4.5% rate after 2014, p <
0.001). Simultaneous with this change was a significant reduction
in initial positive margin rate. This may reflect the incorporation of
surgical techniques such as use of shave margins and oncoplastic
surgery, which have been shown to reduce positive margin rates
in ILC.15 Other tools to reduce positive margin rates include
intraoperative margin assessment, with some centers reporting
positive margin rates as low as 3.6% when frozen section is
utilized, and potential neoadjuvant approaches to downstage
tumors.19,20 Because ILC tends to have late recurrences, further
study will be needed to evaluate the impact of these management
changes in ILC specifically.21
While the initial positive margin rate of 37.6% after BCS in our
cohort falls within the reported range for ILC, it is still quite high.
While some centers advocate excluding patients at higher risk for
positive margins from undergoing BCS (e.g., those with T3 tumors
or multifocality)22 we do not routinely exclude these patients from
attempting BCS provided that they understand the associated
risks and make an informed decision to proceed. This inclusion of
higher risk patients may contribute to high positive margin rates.
This study has several strengths, including the careful review of
outcomes on multiple surgical procedures, long follow up time,
and the applicability to patients since these findings reflect
standard clinical care decisions outside the context of a clinical
trial. However, one major limitation of retrospective analyses is the
inability to determine which factors drove re-excisions. For
example, some patients may have elected to undergo re-
excision or mastectomy because of personal preference, and
some positive margins may have been left unresected due to a
surgeon’s impression that no breast tissue remained for excision.
This is supported by the finding that the majority of unresected
positive margins were located at the anterior or posterior location,
and standard oncologic resections go from dermis to muscle at
our institution.
These findings provide an in depth analysis of the success rates
of re-excision lumpectomy after the finding of initial positive
margins in ILC, and can be used to help patients make informed
surgical choices. Given a high likelihood of success, attempting re-
excision lumpectomy is reasonable, and, is even more likely to be
successful in patients without nodal involvement. While under-
going any additional surgery is associated with patient morbidity
and potential delay in starting adjuvant therapy, a population
based study of over 11,000 patients with breast cancer found no
survival difference between patients with positive margins who
underwent continued attempt at BCS compared to completion
mastectomy.23
In summary, our report on the success rate of re-excision
lumpectomy for patients with ILC should provide guidance to
both patients and surgeons in making management recommen-
dations in the all too common scenario of finding positive
margins. Although BCS can be successful in many women with
ILC, more work is needed to identify therapeutic approaches that
reduce tumor size and result in lower rates of positive margins for
ILC, and longer term follow-up on the impact of changes in
margin management is necessary.
METHODS
Cohort description
We queried a prospectively maintained surgical database and the
pathology archives at the University of California, San Francisco to identify
patients with the diagnosis of ILC. We identified 675 cases of ILC treated
between 1992 and June 2018. After excluding those with missing surgical
treatment data, de novo stage 4 disease, those missing data for margin
status at first or second excision, those undergoing initial mastectomy, and
those receiving neoadjuvant therapy, we included 314 cases in the
analysis. We collected data on patient demographics, operative details
involving the initial and all subsequent breast cancer operations,
pathology findings, and outcomes including time to local or distant
recurrence. Disease free survival was defined as time from cancer diagnosis
to first recurrence, whether ipsilateral locoregional, or distant; patients
were censored at the time of first recurrence. This study was approved by
the Institutional Review Board at the University of California, San Francisco;
informed consent was not required given no patient contact was needed
for this study.
Surgical margin status and width in 1mm increments were recorded for
all surgical procedures when available. Positive margins were defined as
ink on tumor, as described in clinical pathology reports, based on the
guidelines published by the Society of Surgical Oncology (SSO) and the
American Society for Radiation Oncology (ASTRO) in 2014.16 Successful
BCS was defined as the absence of undergoing mastectomy. Successful re-
excision was defined as a re-excision lumpectomy that resulted in negative
margins. Pathologic staging was assigned according to the American Joint
Committee on Cancer 7th edition.24
Statistical methods
We analyzed the data in Stata 14.2. We used Chi-squared tests and Fisher’s
exact test for categorical variables, the Wilcoxon rank-sum test for
continuous variables, logistic regression, and Cox proportional hazards
models. Two-tailed p values < 0.05 were considered significant.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary.
Table 4. Margin status and management before and after consensus guidelines of 2014
Overall Before 2014 2014–2018 p-value
Final margin width, mm (mean, median, SD) 2.55, 1.5, SD 2.94 2.64, 1.5, SD 3.17 2.34, 1, SD 2.37 0.4978
Positive margins at initial BCS (defined as ink on tumor) 118 (37.6%) 94 (42.7%) 24 (25.5%) 0.009
Cases undergoing re-excision lumpectomy or completion mastectomy
for any indication
139 (44.3%) 120 (54.6%) 19 (20.2%) <0.001
Cases undergoing re-excision lumpectomy or completion mastectomy
for positive margins
102 (86.4%) 85 (90.4%) 17 (70.8%) 0.012
Cases undergoing re-excision lumpectomy or completion mastectomy
for negative margins
37 (18.9%) 35 (27.8%) 2 (2.9%) <0.001
Completion mastectomy rate 68 (21.7%) 61 (27.7%) 7 (4.5%) <0.001
M.L. Piper et al.
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